Chris’ note: Today, we’re turning things over to longtime Casey Research friend and Silicon Valley insider Jeff Brown.
Thanks to his decades of experience in the technology industry, Jeff is one of the best investors I know at spotting groundbreaking developments in the sector… before they hit the mainstream media.
Jeff has an inside track on the biggest breakthroughs – and right now, he says there’s one trend that investors need to pay attention to.
In short, Jeff says the biotech sector is about to transform modern medicine… and that could mean big profits for you in 2020 and beyond. Just a few days ago, Jeff’s readers booked a 339% gain on a biotech company he recommended. And he says this is all just the beginning of a multiyear megatrend.
You can find out more from Jeff below…
By Jeff Brown, editor, Exponential Tech Investor
We’re on the cusp of a complete reordering of health care… and at the very beginning of a major bull run in biotech.
It all has to do with an emerging technology trend called precision medicine.
Let me explain…
These days, we typically wait until we feel sick before we seek medical treatment. Then, we visit a hospital, where our symptoms are treated with varying degrees of success.
Very often, each patient is treated with a “one size fits all” therapy. This approach to medicine is reactionary.
In the very near future, medicine will be proactive and personalized.
We will have our genome – our genetic “blueprint” – sequenced to identify mutations in our genetic code that lead to disease. Then, thanks to CRISPR genetic editing technology, we’ll be able to fix these mutations – these “typos” – in our DNA.
As a reminder, CRISPR can edit our genetic code as if it were software. And thanks to CRISPR, we will cure diseases in patients years before symptoms ever present themselves.
This technology saw a number of remarkable developments last year. In November, I attended a biotechnology conference, the STAT Summit. It was the first year the event was held, and it was fantastic.
One of the most incredible presentations came from Vertex Pharmaceuticals (VRTX) CEO Jeffrey Leiden.
Vertex has been working with a company called CRISPR Therapeutics (CRSP) on a therapy for sickle cell disease and beta thalassemia. Bad mutations in the hemoglobin gene cause these blood disorders. The therapy is CTX001.
Leiden talked about how two patients have been treated with CTX001 so far – one with sickle cell disease and the other with beta thalassemia. And the results have been phenomenal.
The beta thalassemia patient had not needed a blood transfusion in nine months. This is amazing because patients with this disease typically need blood transfusions every 2–4 weeks.
And the sickle cell patient had not suffered a crisis in four months.
And Leiden stated directly, “We have essentially cured these diseases. We have cracked the biology of sickle cell and beta [thalassemia].”
Of course, it is not approved by the Food and Drug Administration (FDA) yet. The next step for Vertex is to expand the clinical trials to another 45 patients. I’m expecting identical results compared to the first two patients.
But going off of Leiden’s comments, it appears CRISPR technology has cured these diseases caused by genetic mutations.
So beta thalassemia and sickle cell disease were the first two, but I predict that CRISPR will cure at least five more diseases caused by genetic mutations in 2020.
To be clear, I don’t expect that five therapies will be approved by the FDA in 2020. But I believe at least five CRISPR therapies will demonstrate in either preclinical or clinical trials that they have cured the diseases they were meant to cure.
The novel therapies for these genetically caused diseases will absolutely continue this year. We are still just at the beginning.
And once the applications of CRISPR are well understood, we’re going to continue to see an explosion of investment in this area.
So investors should pay close attention to biotech this year. We’re at the very beginning of a multiyear bull market for the biotech space. I mean, just think about it…
We have a combination of advanced diagnostic technologies coupled with computer processing power, artificial intelligence, and machine learning. And we have an incredible genetic editing platform like CRISPR.
On top of that, we saw record levels of private investments in the biotechnology sector in 2019. This is all going to lead to a multiyear boom in biotech that will really start in 2020.
We will see an explosion of therapies. There will also be a shorter time between drug discovery and FDA approval because of all these tools we have now. We’re going to also have better-quality drugs that will have fewer side effects and will be highly personalized for each patient.
And once Wall Street sees this, what is it going to do? It will invest more in that space because it finally understands what incredible technological advancements are happening.
It’s going to be like dumping fuel on a fire.
Plus, I predict several early-stage companies developing CRISPR therapies will go public. I have a list of companies I think might. We’ll just have to wait and see. But either way, we’re going to have some great new investment opportunities in this space in 2020.
Editor, Exponential Tech Investor
P.S. Like I said before, we’re at the beginning of a multiyear bull run in biotech. And the best CRISPR companies will be leading the charge.
My readers are already making money on this trend. As mentioned above, just this past Tuesday, we booked a 339% gain on a biotech company that uses CRISPR technology.
However, that doesn’t mean it’s too late to get in on this trend before it takes off in 2020.
Right now, a genetic editing company is working hard to cure a form of genetic blindness. That’s right. This company is working to literally cure blindness. The trial results are expected early this year. And I have good reason to believe they will be positive.
And when that happens, the share price of this small-cap stock will skyrocket. There’s still time to get positioned, but not much. Go right here while you have the chance.